CancerNCT07550192
Oncology Acute Care Follow-up Intervention Study
A study testing Follow-up messaging in people with Cancer, run by University of Texas Southwestern Medical Center at 1 site in United States.
Trial summary
This pragmatic randomized controlled study evaluates an education intervention designed to increase patient engagement with Oncology Acute Care (OAC) services among patients being treated for cancer at Parkland Health. Eligible patients will be randomized to either a control (usual care) arm or an intervention arm. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- Follow-up messaging
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Sep 2026to 31 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years.
- Active cancer diagnosis
- Actively receiving chemotherapy treatment
- ED Arrival within 30 days of chemotherapy treatment
- Discharged home following ED visit, observation, or inpatient stay
- Enrolled in MyChart with valid mobile number and language preference recorded (English or Spanish)
Who cannot join
- Not enrolled in MyChart or lacking a valid mobile phone number.
- Language preference not recorded or not English/Spanish (if messaging is only available in these languages).
- Receiving hospice or palliative care services, where acute symptom management goals may differ.
- Patients admitted directly to inpatient care without ED visit
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Parkland Health
Dallas, Texas, 75235
Arthur Hong, MD, 214-648-3240, Arthur.Hong@utsouthwestern.edu
Kathryn Anderson, MA, 214-648-6357, Kathryn.Anderson@utsouthwestern.edu
About this study
Official title: A Pragmatic Randomized Controlled Crossover Study to Evaluate the Impact of Messaging Interventions on Emergency Department Utilization Among Oncology Patients at Parkland Health
This pragmatic randomized controlled study evaluates an education intervention designed to increase patient engagement with Oncology Acute Care (OAC) services among patients being treated for cancer at Parkland Health.
Eligible patients will be randomized to either a control (usual care) arm or an intervention arm. If a patient in the control group has experiences a subsequent cancer treatment related ED visit without documented OAC engagement, they will be moved to the intervention arm. Patients in the intervention arm will receive an automated MyChart message and text message within 24 hours of hospital discharge reinforcing oncology acute care (OAC) resources, including contact information for the triage line and guidance for when to seek urgent versus emergency care. Messages will be resent at 48 and 72 hours if unviewed. Once the message is viewed, the patient will enter an outcome tracking period to monitor time to subsequent ED visit or OAC contact. Follow-up will occur in 3-month intervals until an outcome is documented or the study ends.
After randomization, patients will be monitored on an observation list for outcomes including OAC contact and cancer treatment-related Emergency Department (ED) visits. Patients who contact OAC clinic will be removed from observation list and complete the study. We will repeat the observation period and document outcomes if the patient has a subsequent cancer treatment-related ED visits without documented OAC engagement.
Read the detailed description
Overview:
This study is a pragmatic randomized controlled crossover trial designed to evaluate the feasibility and impact of structured follow-up messaging interventions on patient engagement with Oncology Acute Care (OAC) services and reduction in cancer treatment-related Emergency Department (ED) visits at Parkland Health.
Recruitment and Enrollment:
Eligible patients will be identified using an automated dashboard through Parkland's Epic electronic health record system based on the inclusion/Exclusion criteria. Patients meeting criteria will be automatically flagged for study enrollment. No active consent will be required as the intervention involves standard communication methods already available to patients (MyChart and text messaging), and the study poses minimal risk.
Randomization and Crossover Design:
Patients will be randomized into one of two arms:
Control Arm (Usual Care): Patients receive standard hospital discharge instructions without additional messaging.
Intervention Arm: Patients receive structured follow-up messages using existing education materials via MyChart and automated text messaging within 24, 48, and 72 hours post-discharge. Patients in the control arm who experience a subsequent cancer treatment related ED visit without documented OAC engagement will be crossed over to the intervention arm.
Messaging Intervention:
Patients randomized to the intervention arm will receive structured follow-up messages aimed at increasing awareness and utilization of Oncology Acute Care (OAC) services. Messaging will be delivered via both MyChart and automated text messages, tailored to the patient's preferred language (English or Spanish).
- Initial Message: Sent within 24 hours post discharge from the ED observation, or inpatient stay (10AM following discharge). This message will include:
- Contact information for the OAC clinic and triage line
- Guidance on when to seek urgent care through OAC versus emergency care, including a reminder that same-day OAC appointments may be available
- Follow-Up Messages: If the initial message is not viewed, it will be resent at 48 hours and again at 72 hours post-discharge. Up to 3 messages will be sent per discharge.
- Message Engagement Tracking: Once a message is viewed, the patient enters an outcome tracking period. The study team will record engagement metrics on whether messages were viewed to assess implementation fidelity.
Outcome Tracking:
The study team will monitor patient medical records for the following:
- Time to next cancer treatment-related ED arrivals (including observation and inpatient admissions)
- Contact with OAC clinic or triage line
- Total hospital visits
Follow-up will occur in 3-month intervals. Patients who engage with the OAC clinic will be removed from the observation list and considered to have completed the study. If a patient has another ED visit without OAC engagement, the observation period will repeat.
Data Collection:
Data will be extracted from Epic and include:
- Message engagement metrics (viewed/unviewed, response rates)
- OAC contact logs
- ED visit records
- Patient demographics and clinical characteristics
Data Analysis Plan:
Descriptive statistics will be used to summarize engagement and outcome data. Time-to event analyses (Kaplan-Meier curves with Cox proportional hazards models) will be used to compare time to ED arrival between arms. Mixed-effects logistic regression will be used to analyze secondary visit county outcomes. Subgroup analyses will explore differential effects by language, cancer type, and prior ED utilization.
- Conditions
- Cancer
- Being tested
- Follow-up messaging
- Keywords
- Oncology Acute Care, Emergency Department Use, Messaging
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Follow-up messagingOther
Patients randomized to the intervention arm will receive structured follow-up messages aimed at increasing awareness and utilization of Oncology Acute Care (OAC) services. Messaging will be delivered via both MyChart and automated text messages, tailored to the patient's preferred language (English or Spanish).
| Study group | Role | What they receive |
|---|---|---|
| Control Arm (Usual Care) | No intervention | Patients receive standard hospital discharge instructions without additional messaging Patients in the control arm who experience a subsequent cancer treatment-related ED visit without documented OAC engagement will be crossed over to the intervention arm. |
| Intervention Arm | Experimental | Patients receive structured follow-up messages using existing education materials via MyChart and automated text messaging within 24, 48, and 72 hours post-discharge. Receives: Other: Follow-up messaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to the next cancer treatment related ED visit.
Evaluate whether structured MyChart + text messaging after hospital/ED discharge decreases time to the next cancer treatment-related ED visit compared with usual care.
Measured: 2 years maximum
Secondary outcomes (4)
Patient Engagement with OAC
Assess whether messaging increases patient engagement with the Oncology Acute Care triage line or clinic before returning to the ED.
Measured: 2 years maximum
Message Engagement
Measure message engagement metrics (viewed, unviewed, and response rates).
Measured: 2 years maximum
Evaluate Feasibility
Evaluate feasibility and implementation fidelity of the messaging workflow within Parkland's Epic environment.
Measured: 2 years maximum
Identify Patient Subgroups
Identify patient subgroups (e.g., language, cancer type, prior ED utilization) where the intervention has the greatest effect on ED utilization or care engagement.
Measured: 2 years maximum
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2026
- Study start1 Sep 2026 (estimated)
- Primary completion1 Sep 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Texas Southwestern Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Arthur Hong, University of Texas Southwestern Medical Center
- Investigators
- Arthur Hong, MD, MPH, Principal investigator, University of Texas Southwestern Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07550192
- Sponsor's protocol ID
- STU20251326
- Status last verified
- Jul 2026
- First submitted
- 17 Apr 2026
- Last updated
- 4 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: We only plan to share aggregate data.
Study at a glance
From the registry record, last updated by the sponsor on 4 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pragmatic Randomized Controlled Crossover Study to Evaluate the Impact of Messaging Interventions on Emergency Department Utilization Among Oncology Patients at Parkland Health
- ClinicalTrials.gov ID
- NCT07550192
- Acronym / sponsor ID
- STU20251326
- Conditions
- Cancer
- Keywords
- Oncology Acute Care, Emergency Department Use, Messaging
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University of Texas Southwestern Medical CenterUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 1 Sep 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 24 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This pragmatic randomized controlled study evaluates an education intervention designed to increase patient engagement with Oncology Acute Care (OAC) services among patients being treated for cancer at Parkland Health.
Eligible patients will be randomized to either a control (usual care) arm or an intervention arm. If a patient in the control group has experiences a subsequent cancer treatment related ED visit without documented OAC engagement, they will be moved to the intervention arm. Patients in the intervention arm will receive an automated MyChart message and text message within 24 hours of hospital discharge reinforcing oncology acute care (OAC) resources, including contact information for the triage line and guidance for when to seek urgent versus emergency care. Messages will be resent at 48 and 72 hours if unviewed. Once the message is viewed, the patient will enter an outcome tracking period to monitor time to subsequent ED visit or OAC contact. Follow-up will occur in 3-month intervals until an outcome is documented or the study ends.
After randomization, patients will be monitored on an observation list for outcomes including OAC contact and cancer treatment-related Emergency Department (ED) visits. Patients who contact OAC clinic will be removed from observation list and complete the study. We will repeat the observation period and document outcomes if the patient has a subsequent cancer treatment-related ED visits without documented OAC engagement.
Detailed description
Overview:
This study is a pragmatic randomized controlled crossover trial designed to evaluate the feasibility and impact of structured follow-up messaging interventions on patient engagement with Oncology Acute Care (OAC) services and reduction in cancer treatment-related Emergency Department (ED) visits at Parkland Health.
Recruitment and Enrollment:
Eligible patients will be identified using an automated dashboard through Parkland's Epic electronic health record system based on the inclusion/Exclusion criteria. Patients meeting criteria will be automatically flagged for study enrollment. No active consent will be required as the intervention involves standard communication methods already available to patients (MyChart and text messaging), and the study poses minimal risk.
Randomization and Crossover Design:
Patients will be randomized into one of two arms:
Control Arm (Usual Care): Patients receive standard hospital discharge instructions without additional messaging.
Intervention Arm: Patients receive structured follow-up messages using existing education materials via MyChart and automated text messaging within 24, 48, and 72 hours post-discharge. Patients in the control arm who experience a subsequent cancer treatment related ED visit without documented OAC engagement will be crossed over to the intervention arm.
Messaging Intervention:
Patients randomized to the intervention arm will receive structured follow-up messages aimed at increasing awareness and utilization of Oncology Acute Care (OAC) services. Messaging will be delivered via both MyChart and automated text messages, tailored to the patient's preferred language (English or Spanish).
- Initial Message: Sent within 24 hours post discharge from the ED observation, or inpatient stay (10AM following discharge). This message will include:
- Contact information for the OAC clinic and triage line
- Guidance on when to seek urgent care through OAC versus emergency care, including a reminder that same-day OAC appointments may be available
- Follow-Up Messages: If the initial message is not viewed, it will be resent at 48 hours and again at 72 hours post-discharge. Up to 3 messages will be sent per discharge.
- Message Engagement Tracking: Once a message is viewed, the patient enters an outcome tracking period. The study team will record engagement metrics on whether messages were viewed to assess implementation fidelity.
Outcome Tracking:
The study team will monitor patient medical records for the following:
- Time to next cancer treatment-related ED arrivals (including observation and inpatient admissions)
- Contact with OAC clinic or triage line
- Total hospital visits
Follow-up will occur in 3-month intervals. Patients who engage with the OAC clinic will be removed from the observation list and considered to have completed the study. If a patient has another ED visit without OAC engagement, the observation period will repeat.
Data Collection:
Data will be extracted from Epic and include:
- Message engagement metrics (viewed/unviewed, response rates)
- OAC contact logs
- ED visit records
- Patient demographics and clinical characteristics
Data Analysis Plan:
Descriptive statistics will be used to summarize engagement and outcome data. Time-to event analyses (Kaplan-Meier curves with Cox proportional hazards models) will be used to compare time to ED arrival between arms. Mixed-effects logistic regression will be used to analyze secondary visit county outcomes. Subgroup analyses will explore differential effects by language, cancer type, and prior ED utilization.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control Arm (Usual Care) | No intervention | –Patients receive standard hospital discharge instructions without additional messaging Patients in the control arm who experience a subsequent cancer treatment-related ED visit without documented OAC engagement will be crossed over to the intervention arm. |
| Intervention Arm | Experimental | Other: Follow-up messagingPatients receive structured follow-up messages using existing education materials via MyChart and automated text messaging within 24, 48, and 72 hours post-discharge. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age ≥ 18 years.
- Active cancer diagnosis
- Actively receiving chemotherapy treatment
- ED Arrival within 30 days of chemotherapy treatment
- Discharged home following ED visit, observation, or inpatient stay
Key exclusion criteria (4 listed)
- Not enrolled in MyChart or lacking a valid mobile phone number.
- Language preference not recorded or not English/Spanish (if messaging is only available in these languages).
- Receiving hospice or palliative care services, where acute symptom management goals may differ.
- Patients admitted directly to inpatient care without ED visit
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Follow-up messagingPatients randomized to the intervention arm will receive structured follow-up messages aimed at increasing awareness and utilization of Oncology Acute Care (OAC) services. Messaging will be delivered via both MyChart and automated text messages, tailored to the patient's preferred language (English or Spanish). | Other | Intervention Arm |
Primary outcome
Time to the next cancer treatment related ED visit.
Time frame: 2 years maximum
Evaluate whether structured MyChart + text messaging after hospital/ED discharge decreases time to the next cancer treatment-related ED visit compared with usual care.
4 secondary outcomes
Patient Engagement with OAC
Time frame: 2 years maximum
Message Engagement
Time frame: 2 years maximum
Evaluate Feasibility
Time frame: 2 years maximum
Identify Patient Subgroups
Time frame: 2 years maximum
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Aug 2026.
- Individual participant dataSharing planned: No. We only plan to share aggregate data.
Related trials for Cancer
RecruitingPhase 2
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Not yet recruiting
Effect of a Health Belief Model Based Digital Nudge Intervention on Breast Cancer Screening
Breast Cancer Screening, Breast Cancer Awareness
Not yet recruiting
The AYA Oncology Self-care Movement
Acute Lymphobkastic Leukemia, Medication Adherence
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
RecruitingPhase 2
The COSMYC Trial (COmbined Suppression of MYC)
Metastatic Castration-resistant Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Arthur Hong, MD, MPH principal investigator
University of Texas Southwestern Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Follow-up messaging in people with Cancer, run by University of Texas Southwestern Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 4 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Arthur Hong, MD, MPH (214-648-3240, Arthur.Hong@utsouthwestern.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to the next cancer treatment related ED visit. (time frame: 2 years maximum). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2026.